The process of adjusting antiepileptic drugs is carefully considered, especially in cases with high-risk factors such as tumor genetic marker (e.g. IDH1 mutant), tumor location (e.g. frontotemporal lobe), the occurrence of interictal epileptiform discharges on EEG, and tumor residual after surgery. Here, IDH1 is linked to neoplasm.